Drugs / Ozanezumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01435993 | Sep 2011 → Jan 2012 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01424423 | Feb → Aug 2010 | multiple sclerosis | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00875446 | May 2009 → Sep 2011 | amyotrophic lateral sclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01753076 | Dec 2012 → Jan 2015 | amyotrophic lateral sclerosis | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ozanezumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01753076 ↗ |
| Known as | GSK1223249 | “Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis” NCT01753076 ↗ |
| Action | Inhibit | “The drug works by inhibiting the protein that prevents nerve growth.” NCT00875446 ↗1“Reticulon-4 inhibitor” CHEMBL2108679 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody raised against Nogo-A” NCT01435993 ↗ |
| Route | Intravenous | “single escalating intravenous (i.v.) doses of GSK1223249” NCT00875446 ↗ |
| Target | RTN4 | “Reticulon-4 inhibitor” CHEMBL2108679 ↗ |